Immix Biopharma, Inc. (IMMX) shareholders
Close on Nov 17, 2026Market cap $515.08MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| JANUS HENDERSON GROUP Ltd. | 9,783,192 | 14.00% | 13G (passive) amendment | Jun 30, 2026 |
| Janus Henderson Group PLC | 9,090,732 | 13.00% | 13G (passive) amendment | May 29, 2026 |
| BlackRock, Inc. | 4,539,819 | 5.50% | 13G (passive) | Sep 30, 2026 |
| Eventide Asset Management, LLC Joint filing with Finny Kuruvilla, M.D. Ph. D. (5.60%), Robin C. John (5.60%) | 3,891,019 | 5.60% | 13G (passive) | Jun 30, 2026 |
| Saturn V Capital Management LP Joint filing with Xiaoying Tian (6.97%) | 3,693,585 | 6.97% | 13G (passive) | Dec 26, 2025 |
| Millennium Management LLC Joint filing with Millennium Group Management LLC (5.30%), Israel A. Englander (5.30%) | 2,812,230 | 5.30% | 13G (passive) | Mar 13, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IMMX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 9,783,192 | 13.68% | $100.82M | New | 0.04% |
| Saturn V Capital Management LP | 4,658,429 | 6.51% | $48.03M | +964,844 | 6.89% |
| Eventide Asset Management, LLC | 3,891,019 | 5.44% | $40.12M | +1,342,000 | 0.54% |
| State Street Corp | 2,996,935 | 4.19% | $30.90M | +2,805,025 | 0.00% |
| BlackRock, Inc. | 2,989,972 | 4.18% | $30.83M | +2,521,595 | 0.00% |
| Deep Track Capital, LP | 2,775,000 | 3.88% | $28.61M | New | 0.42% |
| Vanguard Capital Management LLC | 2,507,122 | 3.50% | $25.85M | +719,128 | 0.00% |
| Opaleye Management Inc. | 2,345,000 | 3.28% | $24.18M | New | 2.19% |
| Millennium Management LLC | 2,066,426 | 2.89% | $21.30M | +316,226 | 0.01% |
| UBS Group AG | 1,941,817 | 2.71% | $20.02M | +1,864,985 | 0.00% |
| Marshall Wace, Llp | 1,794,908 | 2.51% | $18.51M | +153,356 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 1,739,919 | 2.43% | $17.94M | +1,324,918 | 0.00% |
| Wellington Management Group Llp | 1,473,409 | 2.06% | $15.19M | New | 0.00% |
| Great Point Partners LLC | 1,277,642 | 1.79% | $13.17M | +927,642 | 2.49% |
| Geode Capital Management, LLC | 1,201,097 | 1.68% | $12.39M | +737,713 | 0.00% |
| Velan Capital Investment Management LP | 1,085,000 | 1.52% | $11.19M | +345,000 | 6.81% |
| Logos Global Management LP | 1,000,000 | 1.40% | $10.31M | −225,000 | 0.44% |
| Bleichroeder LP | 1,000,000 | 1.40% | $10.31M | – | 1.84% |
| Franklin Resources Inc | 969,120 | 1.35% | $9.99M | +54 | 0.00% |
| Burkehill Global Management, LP | 544,118 | 0.76% | $5.61M | +250,000 | 0.20% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 109 | 56M | 78.6% | 45 / 35 | 13 / 11 | 35M | 1M |
| Q1 2026 | 77 | 27M | 37.8% | 24 / 28 | 13 / 12 | 8M | 4M |
| Q4 2025 | 67 | 24M | 34.1% | 41 / 17 | 6 / 5 | 22M | 0M |
| Q3 2025 | 31 | 3M | 3.9% | 12 / 7 | 4 / 4 | 1M | 0M |
| Q2 2025 | 23 | 2M | 3.2% | 5 / 5 | 4 / 4 | 0M | 1M |
| Q1 2025 | 22 | 3M | 4.1% | 3 / 4 | 9 / 4 | 0M | 0M |
| Q4 2024 | 23 | 3M | 4.0% | 5 / 4 | 6 / 7 | 0M | 1M |
| Q3 2024 | 25 | 4M | 5.7% | 1 / 6 | 4 / 6 | 0M | 1M |
| Q2 2024 | 31 | 4M | 6.2% | 5 / 5 | 12 / 6 | 0M | 1M |
| Q1 2024 | 35 | 5M | 7.3% | 14 / 13 | 4 / 7 | 5M | 0M |
| Q4 2023 | 28 | 1M | 1.1% | 13 / 7 | 3 / 1 | 0M | 0M |
| Q3 2023 | 16 | 0M | 0.6% | 3 / 8 | 0 / 5 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
65 funds held IMMX in Q2 2026, 47% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of IMMX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Eventide Healthcare & Life Sciences Fund | 3,891,019 | 5.44% | $40.12M | 2.24% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,104,035 | 2.94% | $21.69M | 0.20% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,780,495 | 2.49% | $18.36M | 0.00% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,326,256 | 1.85% | $13.67M | 0.11% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,067,981 | 1.49% | $11.01M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 681,413 | 0.95% | $7.03M | 0.01% | Jun 30, 2026 |
| Columbia Small Cap Value Discovery Fund | 483,630 | 0.68% | $4.02M | 0.16% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 449,259 | 0.63% | $3.74M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 370,703 | 0.52% | $3.82M | 0.02% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 357,034 | 0.50% | $2.97M | 0.26% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 298,586 | 0.42% | $2.69M | 0.01% | May 31, 2026 |
| Timber Point Global Allocations Fund | 140,000 | 0.20% | $1.44M | 4.51% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 138,125 | 0.19% | $1.42M | 0.09% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 109,438 | 0.15% | $984.94K | 0.00% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 99,794 | 0.14% | $830.29K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ilya M. Rachman | CEO and Chairman, Director | 1,141,683 | 1.60% | May 29, 2026 |
| Gabriel S. Morris | CFO, President, Director | 718,273 | 1.00% | May 29, 2026 |
| Jane Buchan | Director | 28,705 | 0.04% | May 29, 2026 |
| Helen C. Adams | Director | 181,004 | 0.25% | May 29, 2026 |
| Magda Marquet | Director | 72,342 | 0.10% | May 29, 2026 |
| Jason Hsu | Director | 4,815,163 | 6.73% | May 29, 2026 |
| Nancy T. Chang | Director | 925,130 | 1.29% | May 29, 2026 |
| Carey Ng | Director | 1,051,471 | 1.47% | May 29, 2026 |
| Yekaterina Chudnovsky | Director | 3,247,326 | 4.54% | May 29, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Nancy T. Chang Director | May 22, 2026 | Award | +6,250 | – | – | 428,190 |
| Magda Marquet Director | May 22, 2026 | Award | +6,250 | – | – | 52,342 |
| Yekaterina Chudnovsky Director | May 22, 2026 | Award | +6,250 | – | – | 6,250 |
| Jason Hsu Director | May 22, 2026 | Award | +6,250 | – | – | 899,250 |
| Helen C. Adams Director | May 22, 2026 | Award | +6,250 | – | – | 181,004 |
| Jane Buchan Director | May 22, 2026 | Award | +6,250 | – | – | 28,705 |
| Carey Ng Director | May 22, 2026 | Award | +6,250 | – | – | 26,250 |
| Ilya M. Rachman CEO and Chairman, Director | Dec 10, 2025 | Buy | +746 | $6.67 | $4.98K | 1,141,683 |
| Gabriel S. Morris CFO, Director | Dec 10, 2025 | Buy | +770 | $6.58 | $5.07K | 291,429 |
| Gabriel S. Morris CFO, Director | Dec 8, 2025 | Option exercise | +156,000 | $0.80 | $124.80K | 426,844 |
| Ilya M. Rachman CEO and Chairman, Director | Sep 17, 2025 | Buy | +2,500 | $2.02 | $5.05K | 1,140,937 |
| Gabriel S. Morris CFO, Director | Sep 16, 2025 | Buy | +2,600 | $1.97 | $5.12K | 290,659 |
| Ilya M. Rachman CEO and Chairman, Director | Jun 18, 2025 | Buy | +2,178 | $2.30 | $5.01K | 1,138,437 |
| Gabriel S. Morris CFO, Director | Jun 18, 2025 | Buy | +2,225 | $2.28 | $5.07K | 288,059 |
| Jason Hsu Director | Dec 23, 2024 | Buy | +40,000 | $2.19 | $87.60K | 893,000 |
| Jason Hsu Director | Dec 20, 2024 | Buy | +7,700 | $2.17 | $16.71K | 853,000 |
| Jason Hsu Director | Aug 22, 2024 | Buy | +8,100 | $2.25 | $18.23K | 845,300 |
| Jason Hsu Director | Aug 21, 2024 | Buy | +15,000 | $2.23 | $33.45K | 837,200 |
| Carey Ng Director | Aug 16, 2024 | Buy | +10,000 | $1.86 | $18.60K | 20,000 |
| Jason Hsu Director | Jul 24, 2024 | Buy | +6,000 | $2.15 | $12.90K | 822,200 |
| Jason Hsu Director | Jul 18, 2024 | Buy | +3,200 | $2.07 | $6.62K | 816,200 |
| Ilya M. Rachman CEO and Chairman, Director | Jun 7, 2024 | Buy | +2,600 | $2.13 | $5.54K | 1,136,259 |
| Gabriel S. Morris CFO, Director | Jun 7, 2024 | Buy | +2,500 | $2.12 | $5.30K | 285,834 |
| Gabriel S. Morris CFO, Director | Jun 4, 2024 | Buy | +3,300 | $1.81 | $5.97K | 283,334 |
| Ilya M. Rachman CEO and Chairman, Director | Jun 4, 2024 | Buy | +3,300 | $1.81 | $5.97K | 1,133,659 |
| Gabriel S. Morris CFO, Director | May 20, 2024 | Award | +24,141 | – | – | 270,844 |
| Gabriel S. Morris CFO, Director | May 20, 2024 | Award | +194,218 | – | – | 280,034 |
| Gabriel S. Morris CFO, Director | May 20, 2024 | Award | +24,141 | – | – | 24,141 |
| Magda Marquet Director | May 20, 2024 | Award | +21,155 | – | – | 46,092 |
| Ilya M. Rachman CEO and Chairman, Director | May 20, 2024 | Award | +218,359 | – | – | 1,130,359 |
| Helen C. Adams Director | May 20, 2024 | Award | +74,241 | – | – | 174,754 |
| Jane Buchan Director | May 20, 2024 | Award | +1,127 | – | – | 22,455 |
| Magda Marquet Director | May 15, 2024 | Award | +25,002 | – | – | 25,002 |
| Helen C. Adams Director | May 15, 2024 | Award | +87,740 | – | – | 100,740 |
| Jane Buchan Director | May 15, 2024 | Award | +1,332 | – | – | 21,332 |
| Gabriel S. Morris CFO, Director | May 14, 2024 | Buy | +4,500 | $2.23 | $10.04K | 85,816 |
| Ilya M. Rachman CEO and Chairman, Director | May 14, 2024 | Buy | +4,300 | $2.25 | $9.68K | 912,000 |
| Jason Hsu Director | Dec 11, 2023 | Buy | +31,000 | $4.67 | $144.77K | 813,000 |
| Jason Hsu Director | Dec 8, 2023 | Buy | +25,000 | $4.88 | $122.00K | 782,000 |
| Jason Hsu Director | Sep 15, 2023 | Buy | +7,000 | $2.49 | $17.43K | 757,000 |
| Jason Hsu Director | Sep 14, 2023 | Buy | +10,000 | $2.58 | $25.80K | 750,000 |
| Carey Ng Director | Sep 14, 2023 | Buy | +10,000 | $2.58 | $25.80K | 10,000 |
| Jason Hsu Director | Sep 12, 2023 | Buy | +30,000 | $2.83 | $84.90K | 740,000 |
| Helen C. Adams Director | Sep 12, 2023 | Buy | +13,000 | $2.96 | $38.48K | 13,000 |
| Jason Hsu Director | Sep 11, 2023 | Buy | +25,000 | $2.89 | $72.25K | 710,000 |
| Jason Hsu Director | Sep 8, 2023 | Buy | +10,000 | $2.53 | $25.30K | 685,000 |
| Jane Buchan Director | Sep 7, 2023 | Buy | +20,000 | $2.46 | $49.20K | 20,000 |
| Magda Marquet Director | Sep 6, 2023 | Buy | +9,000 | $2.47 | $22.23K | 20,000 |
| Magda Marquet Director | Sep 5, 2023 | Buy | +10,000 | $2.47 | $24.70K | 11,000 |
| Magda Marquet Director | Aug 31, 2023 | Buy | +1,000 | $2.01 | $2.01K | 1,000 |
| Ilya M. Rachman CEO and Chairman, Director | Nov 14, 2022 | Buy | +1,000 | $0.95 | $950 | 907,550 |
| Ilya M. Rachman CEO and Chairman, Director | Nov 14, 2022 | Buy | +4,050 | $1.02 | $4.13K | 906,550 |
| Ilya M. Rachman CEO and Chairman, Director | Nov 14, 2022 | Buy | +150 | $0.99 | $149 | 907,700 |
| Gabriel S. Morris CFO, Director | Nov 14, 2022 | Buy | +5,200 | $0.94 | $4.89K | 81,316 |
| Sean Senn – | Jul 14, 2022 | Sale | −200 | $2.75 | $550 | 899,800 |
| Sean Senn 10% owner | Jul 14, 2022 | Sale | −200 | $2.75 | $550 | 899,800 |
| Vladimir P. Torchilin Scientific Co-Founder | Dec 20, 2021 | Buy | +3,000 | $5.00 | $15.00K | 905,200 |
| Carey Ng Director | Dec 20, 2021 | Conversion | +1,000,221 | $0.85 | $850.19K | 1,000,221 |
| Carey Ng Director | Dec 20, 2021 | Buy | +25,000 | $5.00 | $125.00K | 1,025,221 |
| Jason Hsu Director | Dec 20, 2021 | Buy | +50,000 | $5.00 | $250.00K | 50,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Immix Biopharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 21,822 shares on Sep 3, 2026 over the last 90 days.
See a number that looks wrong?